Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) EBITDA

BRISTOL-MYERS SQUIBB COMPANY (BMY) EBITDA

  • 2026-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $594.00M.
  • 2025-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $1.01B.
  • 2024-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $2.53B.
  • 2023-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $2.43B.

Complete source-backed ebitda history.

Available history
2012-03-31 to 2012-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-03-31Reported(m)(m)$594.00M(m)(m)$347.00M$1.10B$3.42B$2.65B$1.62B$561.00M
2025-03-31Reported(m)(m)$1.01B(m)(m)$260.00M$1.95B$3.03B$2.26B$1.58B$509.00M
2024-03-31Reported(m)(m)$2.53B(m)(m)$284.00M$2.83B$2.93B$2.69B$2.37B$392.00M
2023-03-31Reported(m)(m)$2.43B(m)(m)$278.00M$2.97B$2.57B$2.32B$1.76B$503.00M
2022-03-31Reported(m)(m)$2.58B(m)(m)$253.00M$3.81B$2.47B$2.26B$1.83B$404.00M
2021-03-31Reported(m)(m)$2.67B(m)(m)$173.00M$3.82B$2.84B$2.22B$1.67B$501.00M
2020-03-31Reported(m)(m)$2.48B(m)(m)$186.00M$3.94B$3.66B$2.37B$1.61B$462.00M
2019-03-31Reported(m)(m)$170.00M(m)(m)$204.00M$1.39B$1.82B$1.35B$1.01B$264.00M
2018-03-31Reported(m)(m)$143.00M(m)(m)$239.00M$1.18B$1.58B$1.25B$980.00M$284.00M
2017-03-31Reported(m)(m)$193.00M(m)(m)$291.00M$861.00M(m)$1.30B$1.08B$429.00M
2016-03-31Reported(m)(m)$65.00M(m)(m)$242.00M-$228.00M(m)$1.14B$1.07B$449.00M
2015-03-31Reported(m)(m)$104.00M(m)(m)$136.00M$626.00M(m)$1.02B$1.03B$249.00M
2014-03-31Reported(m)(m)$137.00M(m)(m)$118.00M$617.00M(m)$946.00M$957.00M$49.00M
2013-03-31Reported(m)(m)$213.00M(m)(m)$115.00M-$428.00M(m)$930.00M$994.00M$51.00M
2012-03-31Reported$1.54B(m)(m)(m)29.35%$123.00M$387.00M(m)$909.00M$1.00B$545.00M
2011-03-31Reported(m)$1.29B(m)(m)(m)$75.00M$481.00M(m)$935.00M$928.00M$400.00M

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)(m)$4.01B(m)(m)$1.31B$14.16B$13.94B$9.95B$7.27B$2.27B
2024-12-31Reported(m)(m)$9.60B(m)(m)$1.25B$15.19B$13.97B$11.16B$8.41B$554.00M
2023-12-31Reported(m)(m)$9.76B(m)(m)$1.21B$13.86B$10.69B$9.30B$7.77B$400.00M
2022-12-31Reported(m)(m)$10.28B(m)(m)$1.12B$13.07B$10.14B$9.51B$7.81B$1.37B
2021-12-31Reported(m)(m)$10.69B(m)(m)$973.00M$16.21B$9.94B$10.20B$7.69B$1.08B
2020-12-31Reported(m)(m)$10.38B(m)(m)$753.00M$14.05B$11.77B$10.05B$7.66B$2.12B
2019-12-31Reported(m)(m)$1.75B(m)(m)$836.00M$8.21B$8.08B$6.15B$4.87B$1.51B
2018-12-31Reported(m)(m)$637.00M(m)(m)$951.00M$7.07B$6.47B$6.33B$4.55B$1.02B
2017-12-31Reported(m)(m)$789.00M(m)(m)$1.05B$5.28B$6.01B$6.47B$4.75B$4.16B
2016-12-31Reported(m)(m)$382.00M(m)(m)$1.22B$3.06B$4.97B$5.01B$4.98B$1.41B
2015-12-31Reported(m)(m)$376.00M(m)(m)$820.00M$2.10B(m)$5.92B$4.84B$446.00M
2014-12-31Reported(m)(m)$467.00M(m)(m)$526.00M$3.15B(m)$4.53B$4.82B$352.00M
2013-12-31Reported(m)(m)$763.00M(m)(m)$537.00M$3.54B(m)$3.73B$4.94B$311.00M
2012-12-31Reported(m)(m)$681.00M(m)(m)$548.00M$6.94B(m)$3.90B$4.22B-$161.00M
2011-12-31Reported(m)(m)$628.00M(m)(m)$367.00M$4.84B(m)$3.84B$4.20B$1.72B
2010-12-31Reported(m)(m)$607.00M(m)(m)$424.00M$4.49B(m)$3.57B$3.69B$1.56B

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64